Corporate Governance

Equasens Group’s Board of Directors ensures the application of the principles of good governance based on a respect of ethical business practices and transparency as well as the interests of the company, its shareholders and stakeholders.

The Board’s work, which brings together a range of expertise and complementary experience, is focused on strategic issues, and in particular, increasing the company’s value.

The Board’s work, which brings together a range of expertise and complementary experience, is focused on strategic issues, and in particular, increasing the company’s value.

The Board remains informed throughout the year of the Group’s business activity and results, market trends and expectations of patients and healthcare professionals throughout Europe. It studies acquisition projects and monitors the integration of recently acquired businesses.

The Directors regularly meet with the Group’s key executives. This transparent and construc-tive dialogue provides the basis for shared strategic vision that executive management is in consequence able to implement with confidence.

Composition of the Board of Directors as at 01.07.2023

The Audit and Compensation Committee

The Audit Committee is a standing committee established by the Board of Directors to work with it on its business. As a permanent body, the Audit Committee’s main mission is to monitor the preparation of accounting and financial information and the efficacy of the Group’s internal control and risk management systems. It is also responsible for overseeing the audit of the annual and consolidated financial statements by the Statutory Auditors and monitoring their independence.

In 2022, The Board expanded the Audit Committee’s scope by adding the duties of Compensation Committee. The Compensation Committee is responsible for ensuring that executive compensation and changes thereto are aligned with the interests of shareholders and company’s performance (compensation to attract, incentivise and retain the best executives), and making proposals or recommandations to the Board of Directors.

In 2022, the Audit Committee has three members, all appointed by the Board of Directors:

Ms. Marie-Louise LIGER (Independent Director)
Ms. Anne LHOTE (Director)
Mr. Daniel ANTOINE (Director)
Mr. François JACQUEL (Director)

This Committee is chaired by Ms. Marie-Louise LIGER based on her specific expertise in the area of accounting and finance.

 The Strategy and CSR Committee

In 2022, the Board set up a specialised committee in order to examine how the company integrates CSR issues into its operations and strategy.

The Strategy and CSR Committee will be responsible for :

• Advising the Board of Directors on the Company’s major strategic orientations and, in particular, on areas of development, external growth or divestment opportunities, significant agreements of partnerships and transactions involving the Company’s capital;

• Monitoring changes in the competitive environment. The CSR Committee identifies the most important CSR issues for the Company, and in particular those issues that pose risks and those that present opportunities.

In 2022, the Strategy and CSR Committee was composed of three members :

M. Thierry CHAPUSOT (Chairman of the Board of Directors)
Mrs Céline GRIS (Independant Director)
Mrs Sophie MAYEUX (Independant Director).

The Strategy and CSR Committee is chaired by Thierry CHAPUSOT, given his knowledge of the Group, his expertise, particularly in external growth areas, and his desire to lead the Strategy and CSR Committee by establishing social and environmental responsibility as a priority for the Board he chairs, in order to become a major focus of the Group strategy.

Auditors

SA BATT AUDIT
58, Boulevard d’Austrasie
54000 NANCY
Renewed on 29 June 2020 until the Annual General Meeting called to approve the financial statements for the year ending on 31 December 2025.
Represented by Ms. Jehanne GARRAIT since 2023.

KPMG SA
Tour EQHO – 2 Avenue Gambetta – CS 60055
92066 PARIS LA DEFENSE Cedex
First appointed on 29 June 2023 until the Annual General Meeting called to approve the financial statements for the year ending on 31 December 2028. Represented by M. Bertrand ROUSSEL.